AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Specialty & Advanced Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Symbol: NYSE:ABBV
- CUSIP: 00287Y10
- Web: www.abbvie.com
- Market Cap: $118.78 billion
- Outstanding Shares: 1,591,540,000
- 50 Day Moving Avg: $71.21
- 200 Day Moving Avg: $65.76
- 52 Week Range: $55.06 - $75.04
Sales & Book Value:
- Trailing P/E Ratio: 19.34
- Foreward P/E Ratio: 11.43
- P/E Growth: 0.93
- Annual Revenue: $26.22 billion
- Price / Sales: 4.53
- Book Value: $3.14 per share
- Price / Book: 23.77
- Annual Dividend: $2.56
- Dividend Yield: 3.5%
- EBIDTA: $11.15 billion
- Net Margins: 24.07%
- Return on Equity: 148.83%
- Return on Assets: 12.18%
- Debt-to-Equity Ratio: 7.31%
- Current Ratio: 1.76%
- Quick Ratio: 1.60%
- Average Volume: 5.55 million shs.
- Beta: 1.51
- Short Ratio: 5.37
Frequently Asked Questions for AbbVie (NYSE:ABBV)
What is AbbVie's stock symbol?
AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."
How often does AbbVie pay dividends? What is the dividend yield for AbbVie?
AbbVie declared a quarterly dividend on Friday, June 23rd. Shareholders of record on Friday, July 14th will be given a dividend of $0.64 per share on Tuesday, August 15th. This represents a $2.56 dividend on an annualized basis and a yield of 3.43%. The ex-dividend date of this dividend is Wednesday, July 12th. View AbbVie's Dividend History.
How will AbbVie's stock buyback program work?
AbbVie announced that its board has authorized a stock repurchase plan on Sunday, April 9th 2017, which authorizes the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 5% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company's management believes its shares are undervalued.
How were AbbVie's earnings last quarter?
AbbVie Inc. (NYSE:ABBV) released its quarterly earnings data on Thursday, April, 27th. The company reported $1.28 EPS for the quarter, topping analysts' consensus estimates of $1.26 by $0.02. The firm had revenue of $6.54 billion for the quarter, compared to analyst estimates of $6.49 billion. AbbVie had a net margin of 24.07% and a return on equity of 148.83%. The company's revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.15 earnings per share. View AbbVie's Earnings History.
When will AbbVie make its next earnings announcement?
What guidance has AbbVie issued on next quarter's earnings?
AbbVie updated its FY17 earnings guidance on Thursday, April, 27th. The company provided earnings per share guidance of $5.44-5.54 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.49.
Where is AbbVie's stock going? Where will AbbVie's stock price be in 2017?
13 brokers have issued 1-year price targets for AbbVie's stock. Their forecasts range from $60.00 to $94.00. On average, they anticipate AbbVie's share price to reach $74.58 in the next twelve months. View Analyst Ratings for AbbVie.
What are analysts saying about AbbVie stock?
Here are some recent quotes from research analysts about AbbVie stock:
- 1. According to Zacks Investment Research, "AbbVie’s key drug Humira is performing well and should continue to be driven by growing awareness, favorable clinical data, new indications and expansion into new markets. Moreover, Imbruvica has multi-billion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. Investor focus will be on the stock with several late-stage data-readouts are expected in 2017. AbbVie’s shares outperformed the large-cap pharma industry so far this year. However, Viekira faces intense pricing and competitive pressure in the HCV market. Though Humira is doing well, the company is concerned about the product’s long-term prospects owing to the potential biosimilar competition. Estimates remained stable ahead of the company’s Q2 earnings release. AbbVie has had a mixed record of earnings surprises in the recent quarters. " (7/13/2017)
- 2. Jefferies Group LLC analysts commented, "ABBV's IPR with CHRS will be heard this week, which looks challenging in light of the prior institution decision. However, the market already expects ABBV to lose and we do not see the '135 patent alone as critical to delaying biosimilars, indicating positive asymmetry in our view. We look at the key IPR arguments as well as the risk/ reward around the decision expected in May as we prepare to attend the hearing." (2/14/2017)
- 3. Argus analysts commented, "strong" second quarter earnings print.The analysts noted that not only were AbbVie's results driven by sales of Humira and Imbruvica, but its pipeline also "strengthened" following the acquisition of Stemcentrix and a partnership with Boehringer Ingelheim for the commercial rights of a new immunology drug that is in a late stage trial.The analysts also stated that the earnings print confirmed Imbruvica's "rapid acceptance" which bodes well for future sales. Coupled with the Venclexta drug, AbbVie boasts two "powerful drugs" to treat first- and second-line CLL and other hematogical malignancies.Related Link: Investors Cheer AbbVie's Q2 Numbers, ForecastThe analysts also stated that AbbVie's stock is "attractively valued" at just 11.2x their 2017 earnings per share estimate, which is "well below" the average multiple of 14.5 of other companies under Argus' coverage.Finally, the analysts boosted their full-year 2016 adjusted earnings per share estimate to $4.84 from $4.80 and their 2017 earnings per share estimate to $5.95 from $5.90."The company has strengthened its product portfolio and pipeline through several deals over the past 12 months, and continues to post strong sales of Humira, aided by new indications," (8/8/2016)
Are investors shorting AbbVie?
AbbVie saw a decline in short interest during the month of June. As of June 30th, there was short interest totalling 24,405,917 shares, a decline of 16.2% from the June 15th total of 29,134,909 shares. Based on an average trading volume of 6,120,148 shares, the days-to-cover ratio is presently 4.0 days. Approximately 1.5% of the shares of the company are short sold.
Who are some of AbbVie's key competitors?
Some companies that are related to AbbVie include ConvaTec Group PLC (CTEC), Mallinckrodt PLC (MNK), Indivior PLC (INDV), Supernus Pharmaceuticals (SUPN), Repligen Corporation (RGEN), TherapeuticsMD (TXMD), TherapeuticsMD (TXMD), Eagle Pharmaceuticals (EGRX), Aimmune Therapeutics (AIMT), Rockwell Medical (RMTI), Assembly Biosciences (ASMB), Novan (NOVN), Check-Cap (CHEK), CorMedix (CRMD), Advanced Accelerator Applications S.A. (AAAP), DARA Biosciences (DARA), Macrocure Ltd (MCUR) and Salix Pharmaceuticals (SLXP).
Who are AbbVie's key executives?
AbbVie's management team includes the folowing people:
- Richard A. Gonzalez, Chairman of the Board, Chief Executive Officer
- William J. Chase, Executive Vice President, Chief Financial Officer
- Michael Severino M.D., Executive Vice President - Research & Development, Chief Scientific Officer
- Laura J. Schumacher, Executive Vice President, External Affairs, General Counsel and Corporate Secretary
- Carlos Alban, Executive Vice President - Commercial Operations
- Henry O. Gosebruch, Executive Vice President, Chief Strategy Officer
- Timothy J. Richmond, Senior Vice President - Human Resources
- Azita Saleki-Gerhardt Ph.D., Senior Vice President - Operations
- Robert A. Michael, Vice President, Controller
- Robert J. Alpern M.D., Independent Director
Who owns AbbVie stock?
AbbVie's stock is owned by a number of of institutional and retail investors. Top institutional investors include US Bancorp DE (0.18%), Bank of Montreal Can (0.13%), APG Asset Management N.V. (0.10%), Chevy Chase Trust Holdings Inc. (0.09%), NN Investment Partners Holdings N.V. (0.09%) and National Pension Service (0.08%). Company insiders that own AbbVie stock include Carlos Alban, Laura J Schumacher, Richard A Gonzalez, Robert A Michael, Thomas A Hurwich, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.
Who sold AbbVie stock? Who is selling AbbVie stock?
AbbVie's stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Atalanta Sosnoff Capital LLC, Armstrong Shaw Associates Inc. CT, Exxonmobil Investment Management Inc. TX, Sit Investment Associates Inc., Nisa Investment Advisors LLC, Factory Mutual Insurance Co. and Meeder Asset Management Inc.. Company insiders that have sold AbbVie stock in the last year include Carlos Alban, Laura J Schumacher, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.
Who bought AbbVie stock? Who is buying AbbVie stock?
AbbVie's stock was bought by a variety of institutional investors in the last quarter, including Mn Services Vermogensbeheer B.V., NN Investment Partners Holdings N.V., Pennsylvania Trust Co, National Pension Service, GW&K Investment Management LLC, Manning & Napier Advisors LLC, Aperio Group LLC and Bank of Montreal Can. View Insider Buying and Selling for AbbVie.
How do I buy AbbVie stock?
Shares of AbbVie can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AbbVie's stock price today?
MarketBeat Community Rating for AbbVie (NYSE ABBV)MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of AbbVie stock can currently be purchased for approximately $74.63.
Consensus Ratings for AbbVie (NYSE:ABBV) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||7 Hold Ratings, 5 Buy Ratings, 1 Strong Buy Rating|
|Consensus Rating:||Buy (Score: 2.54)|
|Consensus Price Target: ||$74.58 (0.06% downside)|
Analysts' Ratings History for AbbVie (NYSE:ABBV)
(Data available from 7/21/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|7/20/2017||Credit Suisse Group||Reiterated Rating||Neutral||$65.00 -> $74.00||Medium|
|7/17/2017||Deutsche Bank AG||Reiterated Rating||Hold||$65.00 -> $66.00||Low|
|7/17/2017||Jefferies Group LLC||Reiterated Rating||Buy||$92.00 -> $94.00||Low|
|6/22/2017||Leerink Swann||Reiterated Rating||Market Perform||Low|
|6/22/2017||Societe Generale||Upgrade||Hold -> Buy||Low|
|5/17/2017||BMO Capital Markets||Reiterated Rating||Market Perform||$66.00||Low|
|3/11/2017||Goldman Sachs Group, Inc. (The)||Upgrade||Buy -> Conviction-Buy||$74.00 -> $80.00||N/A|
|12/8/2016||William Blair||Reiterated Rating||Outperform||$76.00||N/A|
|11/28/2016||Citigroup Inc.||Downgrade||Buy -> Neutral||$60.00||N/A|
|9/8/2016||J P Morgan Chase & Co||Downgrade||Overweight -> Neutral||$75.00 -> $73.00||N/A|
|9/1/2016||Raymond James Financial, Inc.||Initiated Coverage||Outperform||$82.00||N/A|
|8/2/2016||Barclays PLC||Reiterated Rating||Equal Weight||$68.00||N/A|
|6/8/2016||Morgan Stanley||Downgrade||Overweight -> Equal Weight||$73.00 -> $65.00||N/A|
|6/6/2016||Cowen and Company||Downgrade||Outperform -> Market Perform||$77.00 -> $70.00||N/A|
|12/18/2015||Atlantic Securities||Initiated Coverage||Neutral||$59.00||N/A|
|7/24/2015||Evercore ISI||Reiterated Rating||Buy||$70.00||N/A|
|7/22/2015||SunTrust Banks, Inc.||Initiated Coverage||Buy||$85.00||N/A|
Earnings History for AbbVie (NYSE:ABBV)Earnings History by Quarter for AbbVie (NYSE ABBV)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/27/2017||Q1 2017||$1.26||$1.28||$6.49 billion||$6.54 billion||View||N/A|
|1/27/2017||Q416||$1.20||$1.20||$6.92 billion||$6.78 billion||View||Listen|
|10/28/2016||Q316||$1.21||$1.21||$6.55 billion||$6.43 billion||View||Listen|
|7/29/2016||Q216||$1.20||$1.26||$6.20 billion||$6.43 billion||View||Listen|
|4/28/2016||Q116||$1.14||$1.15||$6.03 billion||$5.96 billion||View||Listen|
|1/29/2016||Q415||$1.12||$1.13||$6.41 billion||$6.36 billion||View||Listen|
|10/30/2015||Q315||$1.08||$1.13||$5.90 billion||$4.94 billion||View||Listen|
|7/24/2015||Q215||$1.06||$1.08||$5.60 billion||$5.48 billion||View||Listen|
|4/23/2015||Q115||$0.85||$0.94||$718.50 million||$5.04 billion||View||Listen|
|1/30/2015||Q414||$0.86||$0.89||$5.34 billion||$5.45 billion||View||Listen|
|10/31/2014||Q3||$0.77||$0.89||$4.82 million||$5.02 million||View||Listen|
|7/25/2014||Q214||$0.76||$0.82||$4.70 billion||$4.93 billion||View||Listen|
|4/25/2014||Q114||$0.68||$0.71||$4.33 billion||$4.56 billion||View||Listen|
|1/31/2014||Q413||$0.82||$0.82||$5.10 billion||$5.11 billion||View||Listen|
|10/25/2013||Q313||$0.78||$0.82||$4.52 billion||$4.66 billion||View||Listen|
|7/26/2013||Q2 2013||$0.79||$0.92||$4.54 billion||$4.69 billion||View||Listen|
|4/26/2013||Q1 2013||$0.67||$0.68||$4.17 billion||$4.33 billion||View||Listen|
Earnings Estimates for AbbVie (NYSE:ABBV)
Current Year EPS Consensus Estimate: $5.53 EPS
Next Year EPS Consensus Estimate: $6.53 EPS
Current Dividend Information for AbbVie (NYSE:ABBV)
|Dividend Growth:||12.50% (3 Year Average)|
|Payout Ratio:||66.32% (Trailing 12 Months of Earnings) |
46.29% (Based on This Year's Estimates)
39.20% (Based on Next Year's Estimates)
|Track Record:||44 Years of Consecutive Dividend Growth|
Dividend History by Quarter for AbbVie (NYSE ABBV)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for AbbVie (NYSE:ABBV)
Insider Ownership Percentage: 0.23%Insider Trades by Quarter for AbbVie (NYSE:ABBV)
Institutional Ownership Percentage: 68.04%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/14/2017||Carlos Alban||EVP||Sell||45,800||$70.00||$3,206,000.00|| |
|6/14/2017||Laura J Schumacher||Insider||Sell||79,800||$70.00||$5,586,000.00|| |
|5/19/2017||Richard A Gonzalez||Chairman||Sell||71,235||$65.49||$4,665,180.15|| |
|5/18/2017||William J Chase||CFO||Sell||38,300||$65.35||$2,502,905.00|| |
|5/4/2017||Carlos Alban||EVP||Sell||43,000||$67.00||$2,881,000.00|| |
|3/10/2017||Laura J Schumacher||Insider||Sell||40,000||$65.26||$2,610,400.00|| |
|3/10/2017||Robert A Michael||VP||Sell||5,132||$65.29||$335,068.28|| |
|3/10/2017||Timothy J Richmond||SVP||Sell||22,451||$65.29||$1,465,825.79|| |
|3/8/2017||Richard A Gonzalez||Chairman||Sell||72,016||$64.25||$4,627,028.00|| |
|12/2/2016||William J Chase||CFO||Sell||6,600||$59.19||$390,654.00|| |
|9/7/2016||Laura J Schumacher||Insider||Sell||50,000||$65.00||$3,250,000.00|| |
|6/24/2016||Laura J Schumacher||EVP||Sell||186,106||$60.03||$11,171,943.18|| |
|6/2/2016||Richard A Gonzalez||CEO||Sell||285,953||$63.82||$18,249,520.46|| |
|5/11/2016||Richard A Gonzalez||CEO||Sell||39,000||$63.80||$2,488,200.00|| |
|5/10/2016||Carlos Alban||EVP||Sell||47,438||$63.52||$3,013,261.76|| |
|5/10/2016||Thomas A Hurwich||VP||Sell||6,000||$63.59||$381,540.00|| |
|5/10/2016||Timothy J Richmond||SVP||Sell||21,583||$63.52||$1,370,952.16|| |
|3/8/2016||Laura J Schumacher||EVP||Sell||25,000||$56.09||$1,402,250.00|| |
|3/1/2016||Timothy J Richmond||SVP||Sell||12,866||$55.05||$708,273.30|| |
|4/28/2015||Richard A Gonzalez||CEO||Sell||102,964||$64.67||$6,658,681.88|| |
|3/2/2015||Laura J Schumacher||EVP||Sell||25,000||$60.30||$1,507,500.00|| |
|3/2/2015||Timothy J Richmond||SVP||Sell||14,388||$60.33||$868,028.04|| |
|12/22/2014||William J Chase||CFO||Sell||8,495||$68.00||$577,660.00|| |
|3/4/2014||Richard Gonzalez||CEO||Sell||4,799||$51.20||$245,708.80|| |
|3/3/2014||Azita Saleki-Gerhardt||SVP||Sell||2,443||$50.25||$122,760.75|| |
|3/3/2014||Carlos Alban||EVP||Sell||2,882||$50.09||$144,359.38|| |
|3/3/2014||William Chase||CFO||Sell||3,948||$50.22||$198,268.56|| |
|9/17/2013||Azita Saleki-Gerhardt||SVP||Sell||10,473||$45.84||$480,082.32|| |
|8/19/2013||Azita Saleki-Gerhardt||SVP||Sell||1,270||$43.01||$54,622.70|| |
|8/12/2013||Azita Saleki-Gerhardt||SVP||Sell||8,851||$44.91||$397,498.41|| |
|3/11/2013||Edward J Rapp||Director||Buy||2,500||$37.67||$94,175.00|| |
|2/4/2013||Frederick H Waddell||Director||Buy||2,000||$37.05||$74,100.00|| |
Headline Trends for AbbVie (NYSE:ABBV)
Latest Headlines for AbbVie (NYSE:ABBV)
AbbVie (ABBV) Chart for Friday, July, 21, 2017